Kestra Medical Technologies, Ltd.
Income Statement
| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $31.0M | $28.6M | $24.6M | $22.6M | $19.4M | $17.2M | $15.1M | $14.7M |
| Cost of Revenue | $13.5M | $13.0M | $11.6M | $11.1M | $10.5M | $9.6M | $8.5M | $8.9M |
| Gross Profit | $17.5M | $15.7M | $12.9M | $11.4M | $8.9M | $7.6M | $6.5M | $5.8M |
| Gross Margin | 56.5% | 54.8% | 52.6% | 50.6% | 45.7% | 44.3% | 43.4% | 39.6% |
| Operating Expenses | ||||||||
| Research & Development | $6.8M | $5.6M | $5.0M | $4.9M | $4.0M | $5.4M | $3.4M | $3.5M |
| SG&A Expense | $48.4M | $49.4M | $42.7M | $38.3M | $33.7M | $50.5M | $23.8M | $21.5M |
| Operating Income | $-37.7M | $-39.3M | $-34.8M | $-31.8M | $-28.9M | $-48.2M | $-20.6M | $-19.1M |
| Operating Margin | -121.6% | -137.4% | -141.6% | -140.7% | -149.1% | -279.8% | -136.5% | -130.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-44.0M | $-38.6M | $-34.1M | $-32.8M | $-25.8M | $-51.0M | $-21.7M | $-20.6M |
| Income Tax Expense | $50.0K | $192.0K | $35.0K | $34.0K | $33.0K | $102.0K | $18.0K | $8.0K |
| Net Income | $-44.1M | $-38.8M | $-34.2M | $-32.8M | $-25.8M | $-52.1M | $-21.5M | $-20.4M |
| Net Margin | -142.3% | -135.6% | -139.2% | -145.3% | -133.3% | -302.1% | -142.5% | -138.5% |
| EPS (Basic) | $-0.75 | $-0.68 | $-0.31 | $-0.32 | $-0.25 | $-0.79 | $-0.63 | $-0.60 |
| EPS (Diluted) | $-0.75 | $-0.68 | $-0.31 | $-0.32 | $-0.25 | $-0.79 | $-0.63 | $-0.60 |
| Shares Outstanding (Basic) | 58.6M | 54.2M | 111.7M | 102.8M | 102.6M | 49.2M | 39.8M | 39.8M |
| Shares Outstanding (Diluted) | 58.6M | 54.2M | 111.7M | 102.8M | 102.6M | 49.2M | 39.8M | 39.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |